Lamivudina Mylan Pharma

Lamivudine, the active ingredient in Lamivudina Mylan Pharma, is a nucleoside reverse transcriptase inhibitor (NRTI) presented as an oral tablet for oral use. It is used to treat HIV infection in adults and children and to manage chronic hepatitis B infection. Lamivudine works by inhibiting the viral reverse transcriptase enzyme, thereby preventing replication of the virus. It is indicated for patients requiring antiretroviral therapy as part of combination regimens and for those with active hepatitis B virus replication.

GNH USA supplies Lamivudina Mylan Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamivudine is employed in antiretroviral therapy and antiviral management of hepatitis B.

- HIV infection: reduces viral load and improves immune function as part of combination antiretroviral therapy. - Chronic hepatitis B: suppresses HBV replication and helps prevent disease progression. - HIV‑1 infection in children: provides pediatric antiviral control when combined with other agents.

Lamivudine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Headache: occasional tension‑type headache. - Fatigue: general tiredness or lack of energy. - Diarrhea: loose stools, usually transient. - Insomnia: difficulty falling or staying asleep. - Abdominal pain: mild discomfort in the stomach area.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially life‑threatening metabolic disturbance. - Severe hepatomegaly with steatosis: significant liver enlargement with fat accumulation. - Pancreatitis: inflammation of the pancreas causing severe abdominal pain. - Hypersensitivity reactions: rash, fever, or anaphylaxis. - Stevens‑Johnson syndrome: severe skin reaction with blistering. - Severe rash: extensive dermatologic reaction requiring medical attention.

When prescribing lamivudine, clinicians should consider several safety measures.

- Monitor liver function: obtain baseline and periodic liver enzyme tests. - Assess renal function: adjust dosing in patients with impaired kidney function. - Evaluate for hepatitis B flare: monitor HBV DNA levels during therapy. - Counsel on adherence: emphasize the importance of taking medication exactly as prescribed. - Avoid use in patients with known hypersensitivity to lamivudine or its excipients. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lamivudine can interact with several other medicines, requiring caution.

Major Interactions (Avoid): - Didanosine: increased risk of pancreatitis. - Stavudine: heightened mitochondrial toxicity. - Rifampin: reduces lamivudine plasma concentrations. - Interferon‑alpha: additive hepatotoxicity. - Certain protease inhibitors (e.g., ritonavir): may require dose adjustment.

Moderate Interactions (Monitor Closely): - Tenofovir: monitor renal function when co‑administered. - NSAIDs: potential increase in renal toxicity. - Alcohol: may exacerbate liver injury. - Live vaccines: reduced efficacy while on therapy. - Hormonal contraceptives: possible decrease in effectiveness.